Enanta Pharmaceuticals, Inc. (ENTA)
NasdaqGS · USD · Healthcare · Biotechnology
$12.00 (+3.09%) as of
Key statistics
- Market cap
- 349.50M
- Forward P/E
- -5.05
- EPS (TTM)
- -2.42
- Dividend yield
- 0.00%
- 52-week range
- 10.22 – 17.15
- Beta
- 0.96
- Revenue (TTM)
- 65.26M
- Profit margin
- -96.89%
- Analyst target
- $21.83
- Volume
- 440.61k
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Watertown, MA, United States
- Employees
- 120
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.